Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma

Chia Nan University of Pharmacy & Science Institutional Repository > 環境永續暨休閒學院 > 環境資源管理系(所) > 期刊論文 > Item 310902800/34681

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34681

標題:	Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
作者:	Kuo, Hsin-Yu Han, Meng-Zhi Liao, Chih-Hsiang Lin, Yih-Jyh Wang, Chung-Teng Chen, Shang-Hung Chang, Ting-Tsung Chen, Po-Jun Lin, Sheng-Hsiang Chen, Chiung-Yu Chuang, Chiao-Hsiung Wu, I-Chin Wu, Juei-Seng Hong, Tzu-Chun Hsieh, Ming-Tsung Lee, Yang-Cheng Wu, Hung-Tsung Tsai, Hong-Ming
貢獻者:	National Cheng Kung University National Cheng Kung University Hospital National Cheng Kung University China Medical University Taiwan Department of Environmental Resources Management, Chia Nan University of Pharmacy & Science National Cheng Kung University National Cheng Kung University Hospital National Cheng Kung University National Cheng Kung University Hospital National Health Research Institutes - Taiwan National Cheng Kung University National Cheng Kung University National Cheng Kung University Hospital National Cheng Kung University National Cheng Kung University National Cheng Kung University Hospital
關鍵字:	checkpoint inhibitors therapy
日期:	2022
上傳時間:	2023-12-11 14:04:53 (UTC+8)
出版者:	MDPI
摘要:	Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investigate the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients in a real-world setting. Patients and methods: A total of 115 patients who received treatment with nivolumab (n = 73) or pembrolizumab (n = 42) in combination with or without tyrosine kinase inhibitors was enrolled. Therapeutic response, survival outcomes, and safety profiles were compared among these groups. Multivariate analysis of survival response was performed using Cox proportional hazards regression. Results: Patients treated with pembrolizumab demonstrated a significantly higher objective response rate than those with nivolumab (38.1% vs. 15.1%; odds ratio 4.18, p = 0.005) regardless of the combination strategies. In addition, pembrolizumab performed a better overall survival (OS) than nivolumab, (34.9 vs. 9.5 months; hazard ratio (HR) = 0.39, p = 0.004). In subgroup analysis, pembrolizumab exhibited favorable OS than nivolumab for monotherapy (HR = 0.16, p = 0.001) or combination therapy (HR = 0.33, p = 0.006) as second-line or later-line (HR = 0.19, p = 0.001) therapy and those with (HR = 0.31, p = 0.006) or without (HR = 0.15, p = 0.004) well-compensated liver disease. The incidence of adverse events was comparable for both treatments. Conclusion: Both pembrolizumab and nivolumab had significant effects for HCC therapy, and pembrolizumab had a significant survival benefit as compared with nivolumab.
關聯:	PHARMACEUTICS, v.14, n.11, 2263
顯示於類別:	[環境資源管理系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	157	檢視/開啟
pharmaceutics14112263.pdf		878Kb	Adobe PDF	29	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....